These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 19500427)

  • 1. Discovery of gene expression-based pharmacodynamic biomarker for a p53 context-specific anti-tumor drug Wee1 inhibitor.
    Mizuarai S; Yamanaka K; Itadani H; Arai T; Nishibata T; Hirai H; Kotani H
    Mol Cancer; 2009 Jun; 8():34. PubMed ID: 19500427
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents.
    Hirai H; Iwasawa Y; Okada M; Arai T; Nishibata T; Kobayashi M; Kimura T; Kaneko N; Ohtani J; Yamanaka K; Itadani H; Takahashi-Suzuki I; Fukasawa K; Oki H; Nambu T; Jiang J; Sakai T; Arakawa H; Sakamoto T; Sagara T; Yoshizumi T; Mizuarai S; Kotani H
    Mol Cancer Ther; 2009 Nov; 8(11):2992-3000. PubMed ID: 19887545
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MK-1775, a small molecule Wee1 inhibitor, enhances anti-tumor efficacy of various DNA-damaging agents, including 5-fluorouracil.
    Hirai H; Arai T; Okada M; Nishibata T; Kobayashi M; Sakai N; Imagaki K; Ohtani J; Sakai T; Yoshizumi T; Mizuarai S; Iwasawa Y; Kotani H
    Cancer Biol Ther; 2010 Apr; 9(7):514-22. PubMed ID: 20107315
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mdm2 inhibition confers protection of p53-proficient cells from the cytotoxic effects of Wee1 inhibitors.
    Li Y; Saini P; Sriraman A; Dobbelstein M
    Oncotarget; 2015 Oct; 6(32):32339-52. PubMed ID: 26431163
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Wee1 inhibition potentiates Wip1-dependent p53-negative tumor cell death during chemotherapy.
    Clausse V; Goloudina AR; Uyanik B; Kochetkova EY; Richaud S; Fedorova OA; Hammann A; Bardou M; Barlev NA; Garrido C; Demidov ON
    Cell Death Dis; 2016 Apr; 7(4):e2195. PubMed ID: 27077811
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MK-1775, a potent Wee1 inhibitor, synergizes with gemcitabine to achieve tumor regressions, selectively in p53-deficient pancreatic cancer xenografts.
    Rajeshkumar NV; De Oliveira E; Ottenhof N; Watters J; Brooks D; Demuth T; Shumway SD; Mizuarai S; Hirai H; Maitra A; Hidalgo M
    Clin Cancer Res; 2011 May; 17(9):2799-806. PubMed ID: 21389100
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MK1775, a selective Wee1 inhibitor, shows single-agent antitumor activity against sarcoma cells.
    Kreahling JM; Gemmer JY; Reed D; Letson D; Bui M; Altiok S
    Mol Cancer Ther; 2012 Jan; 11(1):174-82. PubMed ID: 22084170
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined inhibition of Chk1 and Wee1 as a new therapeutic strategy for mantle cell lymphoma.
    Chilà R; Basana A; Lupi M; Guffanti F; Gaudio E; Rinaldi A; Cascione L; Restelli V; Tarantelli C; Bertoni F; Damia G; Carrassa L
    Oncotarget; 2015 Feb; 6(5):3394-408. PubMed ID: 25428911
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytokinetic effects of Wee1 disruption in pancreatic cancer.
    Chang Q; Chandrashekhar M; Ketela T; Fedyshyn Y; Moffat J; Hedley D
    Cell Cycle; 2016; 15(4):593-604. PubMed ID: 26890070
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Wee1 inhibition by MK-1775 leads to tumor inhibition and enhances efficacy of gemcitabine in human sarcomas.
    Kreahling JM; Foroutan P; Reed D; Martinez G; Razabdouski T; Bui MM; Raghavan M; Letson D; Gillies RJ; Altiok S
    PLoS One; 2013; 8(3):e57523. PubMed ID: 23520471
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical evaluation of the WEE1 inhibitor MK-1775 as single-agent anticancer therapy.
    Guertin AD; Li J; Liu Y; Hurd MS; Schuller AG; Long B; Hirsch HA; Feldman I; Benita Y; Toniatti C; Zawel L; Fawell SE; Gilliland DG; Shumway SD
    Mol Cancer Ther; 2013 Aug; 12(8):1442-52. PubMed ID: 23699655
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sensitization of Pancreatic Cancers to Gemcitabine Chemoradiation by WEE1 Kinase Inhibition Depends on Homologous Recombination Repair.
    Kausar T; Schreiber JS; Karnak D; Parsels LA; Parsels JD; Davis MA; Zhao L; Maybaum J; Lawrence TS; Morgan MA
    Neoplasia; 2015 Oct; 17(10):757-66. PubMed ID: 26585231
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A regimen combining the Wee1 inhibitor AZD1775 with HDAC inhibitors targets human acute myeloid leukemia cells harboring various genetic mutations.
    Zhou L; Zhang Y; Chen S; Kmieciak M; Leng Y; Lin H; Rizzo KA; Dumur CI; Ferreira-Gonzalez A; Dai Y; Grant S
    Leukemia; 2015 Apr; 29(4):807-18. PubMed ID: 25283841
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Skin equivalents: a tool for the discovery and validation of pharmacodynamic biomarkers.
    Paolini C; Orecchia A; Failla CM; Gallinari P; Zambruno G; Steinkühler C
    Cancer Invest; 2013 Jan; 31(1):60-6. PubMed ID: 23327193
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MK-1775, a novel Wee1 kinase inhibitor, radiosensitizes p53-defective human tumor cells.
    Bridges KA; Hirai H; Buser CA; Brooks C; Liu H; Buchholz TA; Molkentine JM; Mason KA; Meyn RE
    Clin Cancer Res; 2011 Sep; 17(17):5638-48. PubMed ID: 21799033
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Forced mitotic entry of S-phase cells as a therapeutic strategy induced by inhibition of WEE1.
    Aarts M; Sharpe R; Garcia-Murillas I; Gevensleben H; Hurd MS; Shumway SD; Toniatti C; Ashworth A; Turner NC
    Cancer Discov; 2012 Jun; 2(6):524-39. PubMed ID: 22628408
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cell cycle regulation by the Wee1 inhibitor PD0166285, pyrido [2,3-d] pyimidine, in the B16 mouse melanoma cell line.
    Hashimoto O; Shinkawa M; Torimura T; Nakamura T; Selvendiran K; Sakamoto M; Koga H; Ueno T; Sata M
    BMC Cancer; 2006 Dec; 6():292. PubMed ID: 17177986
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The contribution of DNA replication stress marked by high-intensity, pan-nuclear γH2AX staining to chemosensitization by CHK1 and WEE1 inhibitors.
    Parsels LA; Parsels JD; Tanska DM; Maybaum J; Lawrence TS; Morgan MA
    Cell Cycle; 2018; 17(9):1076-1086. PubMed ID: 29895190
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Abrogating G₂/M checkpoint through WEE1 inhibition in combination with chemotherapy as a promising therapeutic approach for mesothelioma.
    Indovina P; Marcelli E; Di Marzo D; Casini N; Forte IM; Giorgi F; Alfano L; Pentimalli F; Giordano A
    Cancer Biol Ther; 2014 Apr; 15(4):380-8. PubMed ID: 24365782
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumour suppressive effects of WEE1 gene silencing in breast cancer cells.
    Ghiasi N; Habibagahi M; Rosli R; Ghaderi A; Yusoff K; Hosseini A; Abdullah S; Jaberipour M
    Asian Pac J Cancer Prev; 2014 Jan; 14(11):6605-11. PubMed ID: 24377575
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.